Overview
The Oncology Care Model (OCM) was a CMMI payment program that ran 2016–2022, providing monthly enhanced-services payments and performance-based shared-savings to oncology practices caring for Medicare beneficiaries during six-month chemotherapy episodes. The Enhancing Oncology Model (EOM), launched 2023, succeeds OCM with design refinements addressing lessons learned and expanded equity requirements.
OCM introduced the six-month oncology episode concept: an episode began when a beneficiary initiated chemotherapy for cancer and ran six months regardless of treatment course, encompassing all services (chemotherapy, imaging, supportive care, hospitalizations) during that window. Practices received a Monthly Enhanced Oncology Services (MEOS) payment per episode plus a performance-based payment tied to TCOC and quality performance.
EOM retains the six-month episode architecture with modifications. Fewer cancer types qualify (seven cancers including breast, colorectal, lung, lymphoma, multiple myeloma, prostate, and small cell lung — more-focused than OCM's broader inclusion). Downside risk is mandatory from EOM's first performance year rather than phased in as OCM did. Quality measurement is simplified and includes equity-focused measures. Monthly payment structures have been recalibrated based on OCM evaluation findings.
Operational priorities for participating practices include comprehensive survivorship planning, aggressive symptom management to prevent emergency-department visits (a significant TCOC driver in oncology episodes), adherence to oral oncology therapies, patient navigation and social-determinant support, and 24/7 access to oncology-trained clinicians.
OCM's performance evaluation produced mixed results. Early performance periods showed modest TCOC reductions and quality maintenance; later periods showed continued improvement. Several participating practices reported meaningful operational transformation driven by the model's requirements. EOM's design incorporates these lessons while addressing concerns about target-price fairness, social-risk adjustment, and small-practice viability.
For oncology RCM, EOM participation introduces episode-payment financial mechanics alongside continuing FFS billing for non-episode services. Six-month episode tracking, performance-period reconciliation, and downside-risk reserving create new finance-function responsibilities. Integration with radiation oncology, surgical oncology, and palliative-care service lines requires cross-specialty financial coordination.
From a finance-leadership view, Oncology Care Model (OCM) / Enhancing Oncology Model (EOM) is one of a handful of metrics that quietly pay for themselves every time they improve. A disciplined program that keeps Oncology Care Model (OCM) / Enhancing Oncology Model (EOM) within a target band reduces working-capital lock-up, shortens the gap between posted charge and collected cash, and — because the same front-end workflows improve bundled payment at the same time — compounds the benefit on adjacent measures too. The editorial convention on this site is to read Oncology Care Model (OCM) / Enhancing Oncology Model (EOM) together with the alternative payment model curve, because the two together describe whether a practice is collecting faster, writing off less, or simply trading one problem for another.
Industry benchmark
OCM enrollment at peak: ~175 oncology practices. EOM enrollment: ~44 practices (2024). OCM evaluations: approximately 1.5–2.5% TCOC savings per episode for participating practices versus FFS comparison.
Worked example
A multi-site oncology practice enrolls in EOM with 2,400 episodes per year across the seven eligible cancer types. MEOS payments total approximately $12M annually. Performance-based payment in year 1 adds $1.8M based on 3.1% TCOC savings against benchmark. Downside-risk reserves cover approximately $800K of potential clawback in future years.
Frequently asked questions — Oncology Care Model (OCM) / Enhancing Oncology Model (EOM)
What cancer types are included in EOM?
Seven: breast, colorectal, lung, lymphoma, multiple myeloma, prostate, and small cell lung. OCM had broader inclusion; EOM focused on cancers with sufficient episode volume and measurement reliability.
Is EOM downside-risk mandatory?
Yes from performance year 1, unlike OCM's phased approach. This reflects the broader CMMI trend toward mandatory downside-risk in new payment models.
How does EOM affect oncology practice revenue?
Net effect depends on TCOC performance. MEOS payments add predictable monthly revenue; performance payments can add materially in successful years; downside-risk creates potential clawback. Most participating practices report modest net positive financial impact alongside care-model transformation benefits.
Disclaimer
This glossary entry is operational reference for revenue-cycle and medical-billing professionals. It is not legal, clinical, or contractual advice. Industry benchmarks cite named public sources where available; always verify against the current guidance from the authority body before relying on a number in a contract, policy, or compliance filing.